It is with pride and gratitude that we reflect on the remarkable 10-year journey of European Journal of Arrhythmia & Electrophysiology. With the vital contributions of all of our esteemed authors, reviewers and editorial board members, the journal has served ...

The Ground-BrEAking Electroporation-based inTervention for Atrial Fibrillation (BEAT-AF) treatment project is an initiative funded by the European Commission from the European Union's Horizon 2020 research and innovation programme, and managed under the European Health and Digital Executive Agency (grant number 945125).1,2 The ...

Highlights Failure to target and deliver durable radiofrequency lesions to all functionally critical areas has been identified as an important cause of ventricular tachycardia recurrence and is particularly challenging in deep midmyocardial or very extensive substrate where point-by-point radiofrequency ablation ...

Catheter ablation has emerged as an effective strategy for the treatment of atrial fibrillation (AF), even becoming a first-line option for selected patients.1 Pulmonary vein isolation (PVI) is the cornerstone of this procedure. Ablation beyond PVI is often practised, but ...

Atrial fibrillation (AF) is the most common type of treated cardiac arrhythmia. The prevalence of the condition increases with age, and it presents with a wide spectrum of symptoms and severity. As the population ages, particularly in developed countries, the ...

Introduction: Pulsed field ablation (PFA) is a novel, non-thermal, atrial fibrillation (AF) ablation technique, in which delivery of millisecond electrical pulses generates pores in cell membranes, leading to its disruption (electroporation). PFA has demonstrated high selectivity for cardiomyocytes, thus reducing ...